SQZ Biotechnologies, a Massachusetts-based clinical-stage biotechnology company, is focused on utilizing the complete potential of cell therapies targeting multiple therapeutic areas with a motto of “Empowering Cells to Change Lives”.
The company announced on Thursday, July 1, the appointment of new expertise Bernard Coulie, M.D., Ph.D., and Patrick Vinc, M.D., welcoming them to the company’s board of directors table, incorporating insights of global commercial and clinical development expertise.
Patrick has previously served as the Vice President managing International Business for Biogen Inc.The company expressed its enthusiasm with the newly appointed board of members suggesting the execution of clinical trials in line with expanding the pipeline addressing multiple disease areas with SQZ novel cell therapies, stated Armon Sharei, Ph.D., Chief Executive Officer of SQZ Biotechnologies.
Be First to Comment